Celyad Oncology (XBRU:CYAD) Days Payable: (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Celyad Oncology Days Payable?

Celyad Oncology's average Accounts Payable for the six months ended in Dec. 2025 was €0.72 Mil. Celyad Oncology's Cost of Goods Sold for the six months ended in Dec. 2025 was € Mil.

The historical rank and industry rank for Celyad Oncology's Days Payable or its related term are showing as below:

XBRU:CYAD' s Days Payable Range Over the Past 10 Years
Min: 1974.7   Med: 15856.34   Max: 40530.21
Current: 40530.21

During the past 13 years, Celyad Oncology's highest Days Payable was 40530.21. The lowest was 1974.70. And the median was 15856.34.

XBRU:CYAD's Days Payable is ranked better than
97.74% of 707 companies
in the Biotechnology industry
Industry Median: 111.24 vs XBRU:CYAD: 40530.21

Celyad Oncology's Days Payable declined from Dec. 2024 (934.09) to Dec. 2025 (). It may suggest that Celyad Oncology accelerated paying its suppliers.

Celyad Oncology Days Payable Historical Data

* Premium members only.

The historical data trend for Celyad Oncology's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology Days Payable Chart

Celyad Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,362.39 1,440.10 - - -

Celyad Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,006.35 882.98 934.09 927.13 -

XBRU:CYAD vs VRTX, REGN, MRNA: Days Payable Comparison

For the Biotechnology subindustry, Celyad Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Days Payable distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Days Payable falls into.


Celyad Oncology Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Celyad Oncology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (1.233 + 0.511) / 2 ) / -1.91*365
=0.872 / -1.91*365
=N/A

Celyad Oncology's Days Payable for the quarter that ended in Dec. 2025 is calculated as:

Days Payable (Q: Dec. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2025 ) + Accounts Payable (Q: Dec. 2025 )) / count ) / Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=( (0.921 + 0.511) / 2 ) / *365 / 2
=0.716 / *365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology Business Description

Other Exchanges CLYYF:USA0QFK:UK1C0:Germany
Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.